westjtter
2 days ago
With the low volume, the MM can easily move around the share price, and while it feels better to be at $11.50 then $10.76, it is all about the upcoming CC, if we have an upside surprise on revenue and projections we go higher, and if we do not, or God forbid have a downside surprise...we go back down. What will cause the shorts to cover?????
The Viral Vector team has been getting congrats from Nick on Linked In for their performance, so perhaps they will announce some new contracts at the CC in 2-3 weeks...that would be good, but I have learned from past CC disappointments not to get your hopes up too high?!
westjtter
1 week ago
Ya well...that is definitely above my pay grade, although it would certainly be in the interests of the shorts to keep the share price down(the question is why? Trying to keep the market cap down for someone wanting to buy them out down the road?)....as for the convertibles....the question is, at what price would they convert as they are getting a very nice dividend right now on the interest. So if I held this loan and was getting over 7%, what would it take for me to lock in my profits and convert to shares(which may very well go down 10% to 20% depending on when the convert is triggered) being aware of the dilution factor.
$160 million divided by $10 per share equals 16 million shares(but of course that would assume they convert at $10 which they would not)
$160 million divided by $15 per share equals 10.6 million shares or a dilution of approx 15% dilution plus or minus
$160 million divided by $20 per share equals 8 million shares or a dilution factor of 12% plus or minus
So the question is, when/if they convert, would they try and sell immediately or over a month or so, or would they be longer term holders?
In my mind, $15 plus in the short term may be enough to trigger conversion, however they can just sit pretty and collect their interest and wait for a buyout offer any time until the loan comes due and possibly get a much bigger pay day!?
westjtter
1 week ago
We seem to be stuck in this $10 to $10.75 range regardless of what the overall market is doing. The share price never seems to vary much from the $10.50 range...if it closes on the upper end($10.75 plus), you can pretty well count on the share price pulling back the next day, and if it closes closer to the $10 mark, once again you can be assured that it will again move back into the $10.50 range within a couple of days.......all this on lighter than normal volume.
What does this mean? No idea, other than it will take some kind of catalyst to move us to the next level, and not really expecting anything positive or negative until we get more news at our upcoming CC in September. So we coast here and wait for news and volume.
Fingers crosssed that we get a good solid upside surprise in September?
djohn
2 weeks ago
Short interest up 1.6 million
I put the closing price on the date of short reporting.
It sure looks like someone has lost money shorting Avid???
Avid Bioservices, Inc. Common Stock (CDMO) Short Interest
Settlement Date Short Interest Avg. Daily Share Volume
07/31/2024 13,926,941 1,436,604 $10.44
07/15/2024 12,311,618 1,034,321 $8.32
06/28/2024 12,358,079 1,235,553 $7.14
06/14/2024 15,076,940 820,884 $7.09
05/31/2024 11,510,830 805,811 $8.09
05/15/2024 11,862,647 1,220,692 $9.25
04/30/2024 11,056,967 1,071,600 $7.63
04/15/2024 10,322,378 984,233 $7.80
03/28/2024 10,110,394 1,114,601 $6.70
03/15/2024 10,842,004 2,873,857 $6.29
02/29/2024 6,593,041 894,032 $7.68
02/15/2024 5,649,903 992,362 $7.70
cheynew
2 weeks ago
From SeekingAlpha
Facing Valuation Risks Despite Increased Capacity
Aug. 06, 2024 6:23 PM ETAvid Bioservices, Inc. (CDMO) Stock
Myriam Alvarez profile picture
Myriam Alvarez
1.42K Followers
Play
(12min)
Summary
Avid Bioservices expanded its revenue capacity from $120 million to over $400 million, focusing on CGT.
CDMO specializes in cGMP for mammalian cell culture products, ensuring compliance with FDA standards.
The company's backlog increased slightly to $193 million in Q4 2024, indicating steady future revenue potential.
Despite positive growth prospects, financial underperformance and valuation concerns led to a "Sell" rating on the stock.
3d render. Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. COVID-19 mRNA vaccine production platform.
wacomka
Avid Bioservices, Inc. (NASDAQ:CDMO) is a leading contract development and manufacturing organization with over 30 years of expertise in the biopharmaceutical industry. The company serves biotech firms that develop biological treatments for cancer, autoimmune disorders, and infectious diseases. CDMO specializes in current good manufacturing practices [cGMP] for products derived from mammalian cell culture, assuring FDA-revised quality and safety standards in the manufacturing processes. CDMO has also expanded into the cell and gene therapy [CGT] sector and boosted its revenue-generating capacity from $120 million to over $400 million. CDMO is well-positioned to capitalize on the ongoing onshoring drug production trend, generating new opportunities for steady growth. However, despite the positives, CDMO continues to underperform financially. Its mounting losses and my valuation concerns on the stock led to rate CDMO a โSell.โ
Pharma Manufacturing: Business Overview
Avid Bioservices is a contract development and manufacturing organization with over 30 years of experience in biopharmaceutical production. CDMO provides manufacturing services for firms that develop innovative biological treatments for conditions like cancer, autoimmune disorders, and infectious diseases at the clinical and commercial stages. The company specializes in current good manufacturing practices [cGMP] for biopharmaceutical products from mammalian cell culture, encompassing processes for producing biological therapies
westjtter
3 weeks ago
All interesting conjecture....HALO has a $7 B market cap and earnings of just over $300 mil. The last company they bought out(Antares Pharma) in April of 22 was at a 50% premium.
So if you put a 50% premium on Avid, that would work out to $15 per share plus or minus, or roughly $1 Billion. Now HALO could easily handle this as it would secure production, and with their Enhance technology growth showing no signs of slowing down....would give them increased profits along with the tax benefits that have accrued with Avid's losses.
Certainly seems to make sense.....right? Would the board go along with a $15 buyout? I would think probably....right? Would the institutions go along with a $15 buyout? Again I would say probably....right? That just leaves the retail shareholders who don't really count in this kind of scenario.
So HALO wins big(IMO) and of course Avid management and especially Nick...win really big. Most institutions would do just fine, and of course that would leave we retail shareholders with a 50% premium over the trading range of late.
Like I have said before....I could live with $15 if it happened in the short term, but still believe that if we can hang on a little longer and we start filling up some of this excess capacity, we probably have a good shot at $20 plus in a year or so???
I guess we will see which way this one goes!